Zhenzhou, China Clinical Trials

A listing of Zhenzhou, China clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the …

erbb2
solid tumour
HER2
afatinib
epidermal growth factor receptor
Henan Cancer Hospital
 (4.6 away) Contact site
  • 0 views
  • 31 May, 2021
  • +97 other locations
Clinical Study of the Safety and Efficacy of BAT5906 Injection

This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema. BAT5906's phase I study on w-AMD shows that it is safe from 0.3-4.0 mg, and the higher dose (2.5 mg and 4 mg) may maintain …

The First Affiliated Hospital of Zhengzhou University
 (0.8 away) Contact site
  • 0 views
  • 07 Mar, 2021
  • +17 other locations
Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

solid tumor
blu-667
chemotherapy regimen
advanced malignant solid tumor
medullary thyroid carcinoma
Henan Cancer Hospital
 (4.6 away) Contact site
  • 1632 views
  • 15 May, 2021
  • +92 other locations
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

solid tumor
blood urea nitrogen
blood test
fludarabine
renal function tests
The First Affiliated Hospital of Zhengzhou University
 (0.8 away) Contact site
  • 196 views
  • 24 Jan, 2021
  • 1 location
Clinical Study of ICP-192 in Solid Tumors Patients

Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.

neutrophil count
solid tumor
serum bilirubin
advanced malignant solid tumor
cancer
Henan cancer hospital & Affiliated Tumor Hospital of Zhengzhou University
 (4.6 away) Contact site
  • 4 views
  • 05 Jun, 2021
  • +6 other locations
Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer

Study Arms: Patients receive autologous dendritic cells pulsed with antigen peptides ID on days 15, 29, 43,57,71,99,127and 155, and nivolumab IV over 60 minutes on days 15, 29, 43,57,71,85 99 and 113.

solid tumour
platelet count
platinum-based chemotherapy
measurable disease
lung carcinoma
Henan Cancer Hospital
 (4.6 away) Contact site
  • 1 views
  • 23 Jan, 2021
  • 1 location
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

The purpose of this study is to evaluate the safety,tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally advanced or metastatic hepatocellular carcinoma or gastric/gastroesophageal junction cancer.

metastatic hepatocellular carcinoma
cancer
Henan Cancer Hospital
 (4.6 away) Contact site
  • 16 views
  • 25 Jan, 2021
  • +21 other locations
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

solid tumor
gastric cancer
glioblastoma multiforme
liver cancer
blood urea nitrogen
Henan Provincial People's Hospital
 (0.8 away) Contact site
  • 11 views
  • 15 Feb, 2021
  • 1 location
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 15 patients Phase (globally): Approximately 90 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)

Henan Province Cancer Hospital
 (2.4 away) Contact site
  • 0 views
  • 18 Feb, 2021
  • +34 other locations
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma Chronic Lymphocytic Leukemia or Other B-cell Malignancies

This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.

Research Site
 (0.8 away) Contact site
  • 0 views
  • 30 May, 2021
  • +27 other locations